Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics. These therapeutics are designed to modulate lipid-signaling pathways, including the endocannabinoid system, aiming to address significant unmet medical needs across various diseases and conditions such as anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Artelo is advancing a diverse portfolio of product candidates, including ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist for treating anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal targeting inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor intended for breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company is headquartered in Solana Beach, California, and its shares are listed on the Nasdaq.

Artelo Biosciences

Artelo Biosciences (ARTL) Corporate presentation Summary | Quartr

Google Play

App Store

App links

Article Categories

Prefooter USP - CTA App

Dig deeper into the Visa Inc fundamentals on Quartr.

Features CTA

Product

Use cases

Discover

Resources

Company

email

Features

Platforms

Featured article

Pricing

Contact sales

Simple CTA

events-root

Artelo Biosciences Inc

Phase II data show significant weight gain in cancer anorexia; glaucoma trial results expected soon.

H.C. Wainwright 28th Annual Global Investment Conference

Net loss narrowed, cash improved with $11M financing, but future depends on new funding.

Q2 2026

All proposals, including director elections and share increases, were approved.

AGM 2026

Shareholders urged to vote before July 17, 2026, to ensure quorum and efficient meeting conduct.

Proxy filing

Shareholders can vote on key proposals at the July 17, 2026, annual meeting.

Shareholders will vote on director elections, share authorization, and a major equity issuance.

Multiple clinical milestones expected in the next 18 months across a diverse therapeutic pipeline.

H.C. Wainwright 26th Annual Global Investment Conference 2024

Shareholders will vote on director elections, a large share increase, and a major equity issuance.

Lead drug candidates advance in cancer, pain, and anxiety with strong safety and efficacy data.

Corporate presentation

### Corporate highlights
- Advancing a platform of lipid signaling modulation drug candidates for pain, cancer, anxiety, depression, and other conditions.
- Focused on billion-dollar markets with robust patent estate and proven leadership.

### Pipeline and development programs
- ART27.13: Dual cannabinoid receptor agonist in Phase 2 for cancer-related anorexia/cachexia and glaucoma.
- ART26.12: FABP5 inhibitor in Phase 1 for chemotherapy-induced peripheral neuropathy and other indications.
- ART12.11: CBD:TMP cocrystal in late preclinical for anxiety and depression.

### ART27.13 clinical progress
- Addresses cancer anorexia/cachexia syndrome, affecting up to 80% of advanced cancer patients with no FDA-approved treatment.
- Demonstrated dose-dependent weight gain and increased activity in Phase 2 CARES trial, with a favorable safety profile.
- Also being evaluated in glaucoma for intraocular pressure reduction with minimized CNS side effects.

Artelo Biosciences (ARTL) Corporate presentation summary

Corporate presentation summary

Corporate highlights

Pipeline and development programs

ART27.13 clinical progress

Latest events from Artelo Biosciences